Verapamil and Chemotherapy in Small Cell Lung Cancer
Author Information
Author(s): R. Milroy
Primary Institution: West of Scotland Lung Cancer Research Group
Hypothesis
Can verapamil improve the effectiveness of chemotherapy in small cell lung cancer patients?
Conclusion
The addition of verapamil to chemotherapy did not significantly improve response or survival in small cell lung cancer patients.
Supporting Evidence
- Over 75% of patients completed all four cycles of chemotherapy.
- There were no significant differences in general toxicities between the two treatment arms.
- More severe alopecia was observed in the verapamil treatment group.
- Median survival was similar between the verapamil and control groups.
Takeaway
This study tested if a drug called verapamil could help chemotherapy work better for lung cancer, but it didn't make a difference.
Methodology
Patients were randomly assigned to receive either chemotherapy alone or chemotherapy with verapamil, and their responses were measured.
Limitations
The study may have been limited by low blood levels of verapamil in patients compared to effective levels observed in laboratory settings.
Participant Demographics
Patients were aged 70 or less with histologically proven small cell lung cancer and adequate organ function.
Statistical Information
P-Value
P = 0.290
Want to read the original?
Access the complete publication on the publisher's website